ClonoSIGHT™: MRD Detection and Quantification
The first clinical product developed using the LymphoSIGHT platform is the ClonoSIGHT process, which empowers physicians with ultra-sensitive minimal residual disease (MRD) detection and quantification for patients with lymphoid cancers.
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Mantle Cell Lymphoma
Clinical validation of additional indications is ongoing